Dimitrakopoulos I, Magopoulos C, Karakasis D
Department of Oral and Maxillofacial Surgery, Aristotle University of Thessaloniki, Greece.
Int J Oral Maxillofac Surg. 2006 Jul;35(7):588-93. doi: 10.1016/j.ijom.2006.02.022. Epub 2006 May 9.
Bisphosphonates are compounds used in the treatment of various metabolic and malignant bone diseases. In the last 2 years there has been a significant increase in referrals to the Department of Oral and Maxillofacial Surgery of patients with exposed necrotic jaw bone, diagnosed elsewhere as chronic refractory osteomyelitis of jaws, mostly after several teeth extractions. The only clinical feature in common for all the patients was the use of bisphosphonates in the treatment of bone diseases. A retrospective study was performed of 11 patients with necrotic bone lesions of the jaws of various extents referred to this Department from July 2003 to November 2004. The management of the patients included cessation of bisphosphonate therapy for 2-8 months and various surgical restorative procedures thereafter. Four patients (36%) presented with maxillary bone involvement, 6 (55%) had mandibular bone necrosis and 1 (9%) presented with necrosis at 3 quadrants. All patients had received bisphosphonate therapy for 6 months to 5 years. Biopsies from the necrotic lesions revealed no metastatic disease. One patient who was removed from bisphosphonate therapy for 8 months recovered completely, one other who was not removed from bisphosphonate therapy relapsed and for all the others, with cessation of bisphosphonate therapy for 2-6 months, the results were inconsistent. A new complication of bisphosphonate therapy administration, i.e. osteonecrosis of jaws, seems to be developing. The improved results after cessation of the medication should make clinicians reconsider the merits of the rampant use of bisphosphonates, while further investigation is needed to completely elucidate this complication.
双膦酸盐是用于治疗各种代谢性和恶性骨疾病的化合物。在过去两年中,转诊至口腔颌面外科的患者显著增加,这些患者被诊断为暴露性坏死颌骨,在其他地方被诊断为慢性难治性颌骨骨髓炎,大多发生在多次拔牙之后。所有患者唯一的共同临床特征是在治疗骨疾病时使用了双膦酸盐。对2003年7月至2004年11月转诊至本科的11例不同程度颌骨坏死性病变患者进行了回顾性研究。对患者的处理包括停用双膦酸盐治疗2 - 8个月,之后进行各种手术修复程序。4例患者(36%)上颌骨受累,6例(55%)下颌骨坏死,1例(9%)三个象限均出现坏死。所有患者接受双膦酸盐治疗的时间为6个月至5年。坏死病变的活检未发现转移性疾病。1例停用双膦酸盐治疗8个月的患者完全康复,另1例未停用双膦酸盐治疗的患者复发,对于其他所有患者,停用双膦酸盐治疗2 - 6个月后,结果不一致。双膦酸盐治疗给药出现了一种新的并发症,即颌骨坏死,似乎正在发生。停药后改善的结果应促使临床医生重新考虑过度使用双膦酸盐的利弊,同时需要进一步研究以彻底阐明这种并发症。